First Time Loading...

Genus PLC
LSE:GNS

Watchlist Manager
Genus PLC Logo
Genus PLC
LSE:GNS
Watchlist
Price: 1 898 GBX 0.32% Market Closed
Updated: May 12, 2024
Section:
 

Relative Value

The Relative Value of one GNS stock under the Base Case scenario is 3 344.1 GBX. Compared to the current market price of 1 898 GBX, Genus PLC is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GNS Relative Value
Base Case
3 344.1 GBX
Undervaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
92
vs Industry
82
Median 3Y
2.9
Median 5Y
3.4
Industry
8.2
Forward
1.8
More Details
37.5
P/E
P/E
Price to Earnings
37.5
vs History
88
vs Industry
5
Median 3Y
48.4
Median 5Y
54.5
Industry
27.4
Forward
26.8
More Details
28.1
P/OCF
P/OCF
Price to OCF
28.1
vs History
90
vs Industry
6
Median 3Y
46.6
Median 5Y
44.6
Industry
24.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
1
Median 3Y
112.1
Median 5Y
97.7
Industry
23
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
93
vs Industry
42
Median 3Y
3.2
Median 5Y
3.5
Industry
2.6
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
92
vs Industry
68
Median 3Y
3.2
Median 5Y
3.6
Industry
7.5
Forward
2.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
15.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.1
vs History
90
vs Industry
8
Median 3Y
19.8
Median 5Y
23.9
Industry
4.3
Forward
14.8
More Details
28
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28
vs History
85
vs Industry
5
Median 3Y
33.7
Median 5Y
38.9
Industry
4.2
Forward
21
More Details
33.3
EV/OCF
EV/OCF
Enterprise Value to OCF
33.3
vs History
87
vs Industry
5
Median 3Y
49.5
Median 5Y
46
Industry
5.9
More Details
148.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
148.5
vs History
17
vs Industry
1
Median 3Y
67.4
Median 5Y
95.9
Industry
3.3
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
93
vs Industry
54
Median 3Y
2.2
Median 5Y
2.6
Industry
4.9
More Details

Multiples Across Competitors

GNS Competitors Multiples
Genus PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Genus PLC
LSE:GNS
1.3B GBP 1.9 37.5 15.1 28
US
Abbvie Inc
NYSE:ABBV
283.9B USD 5.2 58.9 12.8 19.5
US
Amgen Inc
NASDAQ:AMGN
166.4B USD 5.6 44.2 18.6 30.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.9B USD 11 30.1 24.2 25.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.3B USD 8.2 27.8 22.5 24.9
AU
CSL Ltd
ASX:CSL
134.9B AUD 6.3 36 21.8 27
US
Gilead Sciences Inc
NASDAQ:GILD
82.2B USD 3 169.8 6.8 8.9
US
Moderna Inc
NASDAQ:MRNA
44.9B USD 8.7 -7.5 -8.1 -7.2
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
32.3B USD 3.3 27.6 14.1 17.7
KR
Celltrion Inc
KRX:068270
40T KRW 18.4 74.6 45.6 62.9
EV/EBITDA Multiple
EBITDA Growth
UK
Genus PLC
LSE:GNS
Average EV/EBITDA: 20.2
15.1
30%
US
Abbvie Inc
NYSE:ABBV
12.8
26%
US
Amgen Inc
NASDAQ:AMGN
18.6
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.5
50%
AU
CSL Ltd
ASX:CSL
21.8
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.8
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.1 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
14.1
67%
KR
Celltrion Inc
KRX:068270
45.6
109%

See Also

Summary
GNS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GNS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GNS stock valuation using valuation multiples.
Wall Street Estimates
GNS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GNS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.